Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1067974#aggregation> ?p ?o. }
Showing items 1 to 81 of
81
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B331088.
- aggregation creator B331089.
- aggregation creator B331090.
- aggregation creator B331091.
- aggregation creator B331092.
- aggregation creator B331093.
- aggregation creator B331094.
- aggregation creator B331095.
- aggregation creator B331096.
- aggregation creator B331097.
- aggregation creator B331098.
- aggregation creator B331099.
- aggregation creator B331100.
- aggregation creator B331101.
- aggregation creator B331102.
- aggregation creator B331103.
- aggregation creator B331104.
- aggregation creator B331105.
- aggregation creator B331106.
- aggregation creator B331107.
- aggregation creator B331108.
- aggregation creator B331109.
- aggregation creator B331110.
- aggregation creator B331111.
- aggregation creator B331112.
- aggregation creator B331113.
- aggregation creator B331114.
- aggregation creator B331115.
- aggregation creator B331116.
- aggregation creator B331117.
- aggregation creator B331118.
- aggregation creator B331119.
- aggregation creator B331120.
- aggregation creator B331121.
- aggregation creator B331122.
- aggregation creator B331123.
- aggregation creator B331124.
- aggregation creator B331125.
- aggregation creator B331126.
- aggregation creator B331127.
- aggregation creator B331128.
- aggregation creator B331129.
- aggregation creator B331130.
- aggregation creator B331131.
- aggregation creator B331132.
- aggregation creator B331133.
- aggregation creator B331134.
- aggregation creator B331135.
- aggregation creator B331136.
- aggregation creator B331137.
- aggregation creator B331138.
- aggregation creator B331139.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1067974.bibtex.
- aggregation hasFormat 1067974.csv.
- aggregation hasFormat 1067974.dc.
- aggregation hasFormat 1067974.didl.
- aggregation hasFormat 1067974.doc.
- aggregation hasFormat 1067974.json.
- aggregation hasFormat 1067974.mets.
- aggregation hasFormat 1067974.mods.
- aggregation hasFormat 1067974.rdf.
- aggregation hasFormat 1067974.ris.
- aggregation hasFormat 1067974.txt.
- aggregation hasFormat 1067974.xls.
- aggregation hasFormat 1067974.yaml.
- aggregation isPartOf urn:issn:1471-2407.
- aggregation language "eng".
- aggregation rights "I have retained and own the full copyright for this publication".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma".
- aggregation abstract "Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate antineoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods/Design: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor- free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor- free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor- free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 2(1/2)-year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating.".
- aggregation authorList BK624527.
- aggregation volume "10".
- aggregation aggregates 1072082.
- aggregation isDescribedBy 1067974.
- aggregation similarTo 1471-2407-10-190.
- aggregation similarTo LU-1067974.